宣威女性肺癌中CerbB-2的表达与新辅助化疗的关系及临床意义(2)
当前对CerbB-2基因研究的热点之一是其能否作为新辅助化疗的预测因子,目前各家观点不一。NSABP B11[5]及NASBPB15[6]试验均表明含有蒽环类药物的方案对CerbB-2阳性患者有效。当前国际上主要还是倾向于认为CerbB-2基因的扩增和过度表达的肺癌患对蒽环类药物的联合化疗有效。从本结果可以看出,新辅助化疗组中有效组的CerbB-2阳性率较无效组低,比较差异有统计学意义,提示CerbB-2阳性率的降低与临床疗效有关。但仍有一些研究与此相反。
综上所述,新辅助化疗可降低肺癌患者CerbB-2的阳性表达率, CerbB-2阳性的细胞可能是新辅助化疗的一个作用靶点,最终CerbB-2能否作为宣威肺癌新辅助化疗的预测指标,尚需进一步的研究。
参考文献
1 Nagao M,Nakajima Y, Hisanaga M, et al. The alteration of Fas receptor and ligand system in hepatocellular carci-nomas: how do hepatoma cell escape from the host immue surveillance in vivo Hepatology,1999,30(2):413.
2 Martin J,Ginsberg RJ,Abolhoda A,et al.Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneu-monectomy.Ann Thorac Surg，2001,72(4):1149-1154.
3 SCleator,MPartom,MDowsett.The biology of neoadjuvant chemotherapy for breast cancer. Endocrine Related Cancer,2002,9:183-195.
4 Paik S, Bryant J,Park C,et al.ErbB-2 and response to doxorubicin inpatientswith axillary lymph node positive hormone receptor negative breastcancer . J Natl Cancer Inst, 1998,90:1361-1370.
5 NiskanenE, BlomqvistC, FranssilaK, et al.Predictivevalueof cerbB-2 of p53 cathepsin-D and histology of the primary tumour in metastatic breast cancer.Br J Cancer,1997,76:917-922.
6 Rozan S, Vincent salomonA, Zafrani B, et al. No significant predictive value of cerbB-2 of p53 expression regarding sensitivity to primary or radiotherapy in breast cancer. Int J Cancer,1998,79:27-33., 百拇医药(侯文俊 王巍炜 王 前 李高峰)
综上所述,新辅助化疗可降低肺癌患者CerbB-2的阳性表达率, CerbB-2阳性的细胞可能是新辅助化疗的一个作用靶点,最终CerbB-2能否作为宣威肺癌新辅助化疗的预测指标,尚需进一步的研究。
参考文献
1 Nagao M,Nakajima Y, Hisanaga M, et al. The alteration of Fas receptor and ligand system in hepatocellular carci-nomas: how do hepatoma cell escape from the host immue surveillance in vivo Hepatology,1999,30(2):413.
2 Martin J,Ginsberg RJ,Abolhoda A,et al.Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneu-monectomy.Ann Thorac Surg，2001,72(4):1149-1154.
3 SCleator,MPartom,MDowsett.The biology of neoadjuvant chemotherapy for breast cancer. Endocrine Related Cancer,2002,9:183-195.
4 Paik S, Bryant J,Park C,et al.ErbB-2 and response to doxorubicin inpatientswith axillary lymph node positive hormone receptor negative breastcancer . J Natl Cancer Inst, 1998,90:1361-1370.
5 NiskanenE, BlomqvistC, FranssilaK, et al.Predictivevalueof cerbB-2 of p53 cathepsin-D and histology of the primary tumour in metastatic breast cancer.Br J Cancer,1997,76:917-922.
6 Rozan S, Vincent salomonA, Zafrani B, et al. No significant predictive value of cerbB-2 of p53 expression regarding sensitivity to primary or radiotherapy in breast cancer. Int J Cancer,1998,79:27-33., 百拇医药(侯文俊 王巍炜 王 前 李高峰)